本帖最后由 老马 于 2012-1-13 21:20 编辑
2 Z9 l! |# r) ]! ~, r, T$ {5 ?6 [% G( g( `4 Y
爱必妥和阿瓦斯丁的比较
5 I. Z |* T- O, m/ D& v6 y5 _
- {/ P6 t' q7 Mhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/3 [6 }. l$ z' |) d/ i* T
3 l8 p2 O6 f0 c( y/ g
% f3 {1 \# `2 B3 chttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
6 a/ A1 Z; q# H0 j9 ?==================================================
f( i9 X/ z: V* `Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL): w/ ?7 y _; F1 ]) ^+ f( u
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.! f( y3 R1 e9 M7 g* H4 r" d
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
+ ^/ z" [9 O( H& H! H( P8 t- x: m
|